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mRNA therapeutics hold promise for the treatment of diseases
requiring intracellular protein expression and for use in
genome editing systems, but mRNA must transfect the desired
tissue and cell type to be efﬁcacious. Nanoparticle vectors that
deliver the mRNA are often evaluated using mRNA encoding
for reporter genes such as ﬁreﬂy luciferase (FLuc); however,
single-cell resolution of mRNA expression cannot generally
be achieved with FLuc, and, thus, the transfected cell popula-
tions cannot be determined without additional steps or exper-
iments. To more rapidly identify which types of cells an mRNA
formulation transfects in vivo, we describe a Cre recombinase
(Cre)-based system that permanently expresses ﬂuorescent
tdTomato protein in transfected cells of genetically modiﬁed
mice. Following in vivo application of vectored Cre mRNA, it
is possible to visualize successfully transfected cells via Cre-
mediated tdTomato expression in bulk tissues and with sin-
gle-cell resolution. Using this system, we identify previously
unknown transfected cell types of an existing mRNA delivery
vehicle in vivo and also develop a new mRNA formulation
capable of transfecting lung endothelial cells. Importantly,
the same formulations with mRNA encoding for ﬂuorescent
protein delivered to wild-type mice did not produce sufﬁcient
signal for any visualization in vivo, demonstrating the signiﬁ-
cantly improved sensitivity of our Cre-based system.We believe
that the system described here may facilitate the identiﬁcation
and characterization of mRNA delivery vectors to new tissues
and cell types.
INTRODUCTION
mRNA therapeutics have the potential to address unmet medical
needs by inducing speciﬁc intracellular protein expression in vivo.
mRNA-based therapies have entered clinical trials for vaccine and
protein replacement applications and are being studied pre-clinically
in other areas, such as genome editing.1,2 However, delivery of mRNA
into the target tissue and the cytoplasm of the target cell type remains
challenging for some tissue types. Various vectors, such as lipid and
polymeric nanoparticles, have been utilized to encapsulate and deliver
mRNA payloads intracellularly.3,4 To evaluate the transfection ability,
biodistribution, and pharmacokinetics of these delivery vectors
in vivo, mRNAs coding for reporter genes (e.g., bioluminescent lucif-
erases, ﬂuorescent proteins, b-galactosidase, and others) are often
used to optimize the system before therapeutic mRNA delivery is
attempted.5 Additionally, for most vectored mRNA delivery applica-
tions, it is useful to identify not only the targeted tissue but also the
targeted cell populations within that tissue. For example, cancer im-
munotherapies would ideally express mRNA encoding antigen in
dendritic cells of the lymphatic system;6,7 conversely, protein replace-
ment therapy for cystic ﬁbrosis would target expression of mRNA en-
coding CFTR in lung epithelial cells.8,9
Fireﬂy luciferase (FLuc) mRNA is a commonly used reporter mRNA
in the literature for in vivo studies and has been used to demonstrate
mRNA transfection in the liver,10,11 spleen,12,13 pancreas,11 lung,13,14
bone marrow,13 lymph nodes,13,15 muscle,16,17 and xenograft tu-
mors.18 Upon activation by a nontoxic and stable substrate, FLuc
emits light at tissue-penetrating wavelengths that can be imaged
in vivo,19 making FLuc useful for surveying the entire animal and
identifying mRNA translation in bulk tissues. Thus, this in vivo biolu-
minescence imaging (BLI) technique is a powerful tool to localize pro-
tein expression and guide the researcher to the most appropriate tis-
sue for further in vivo analysis with ﬂuorescent markers.20 However,
the desired single-cell resolution cannot be achieved with FLuc using
conventional techniques such as ﬂow cytometry or microscopy,
which require a strong ﬂuorescent signal, without the use of
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engineered luciferase-ﬂuorescent protein conjugates21–23 or addi-
tional disruptive antibody staining steps requiring membrane perme-
abilization.24,25 In principle, mRNAs encoding ﬂuorescent proteins
can allow for facile single-cell analysis via microscopy or ﬂow cytom-
etry. However, current commercially available GFP and tdTomato
mRNAs delivered to wild-type mice using previously reported formu-
lations and doses did not induce sufﬁcient protein expression to be
visualized in vivo above background ﬂuorescence despite having
strong GFP and tdTomato signals when delivered to cells in vitro
(Figures S1–S3). Thus, there is a need for a mouse model that can
sensitively and rapidly identify mRNA-transfected cell populations
in vivo to optimize mRNA delivery vectors for diverse cellular targets
and clinical applications.
We hypothesized that in vivo delivery of mRNA could be more easily
visualized in a genetically modiﬁed mouse with a loxP-ﬂanked
STOP cassette preventing transcription of a CAG promoter-driven
tdTomato protein in all cells, such as the Ai14 reporter mouse
(Figure 1A).26 In this model, cells that are successfully transfected
with mRNA encoding Cre recombinase (Cre) would excise the
loxP-ﬂanked STOP cassette, resulting in permanent tdTomato tran-
scription and subsequent strong, ampliﬁed tdTomato expression.
To validate this model, we delivered Cre mRNA with two distinct de-
livery vectors to Ai14 mice and analyzed the resultant tdTomato
expression using whole-organ imaging, ﬂuorescence microscopy,
and ﬂow cytometry. In this report, we use this Ai14/Cre mRNA
mouse model to describe vectored mRNA transfection in vivo with
single-cell resolution at low mRNA doses.
RESULTS AND DISCUSSION
Validation of the Ai14/Cre mRNA Model In Vivo
We ﬁrst investigated whether vectored mRNA encoding for GFP or
tdTomato could result in sufﬁcient GFP or tdTomato signal for
whole-organ imaging. An optimized11 lipid nanoparticle (LNP)
formulation (Figures 1B and 1C) capable of achieving high levels of
FLuc mRNA expression predominately in the liver following intrave-
nous administration to mice (LNP-1) has been reported previously.10
The composition of LNP-1 is shown in Figure S4. We formulated
LNP-1 with commercially available GFP or tdTomato mRNA and
administered it intravenously to wild-type C57BL/6 mice at 0.3 mg/
kg. The GFP or tdTomato ﬂuorescence of the liver and two additional
organs (spleen and lungs) was measured at 24 hr, the approximate
half-life of these ﬂuorescent proteins (Figure 2A).27 We found no
detectable GFP or tdTomato signal from LNP-1-administered wild-
type mice at this dose using GFP or tdTomato mRNAs, meaning
that an alternative method of measuring mRNA translation in whole
organs is needed for LNP-1.
We next tested the ability of the hypothesized Ai14/Cre mRNAmodel
to produce measurable tdTomato expression in whole organs. We
formulated Cre mRNA into LNP-1 and administered it intravenously
to Ai14 mice at 0.3 mg/kg. 48 hr post-injection (to provide additional
time for the Cre recombination and transcription steps), there was
tdTomato expression in the liver that was orders of magnitude higher
than background tissue autoﬂuorescence (Figure 2A), demonstrating
that vectored Cre mRNA could generate a tdTomato signal in Ai14
mice as proposed. Furthermore, the liver biodistribution of tdTomato
Figure 1. Ai14/Cre mRNA Mouse Model Description and Lipid Nanoparticle Characterization
(A) Diagram of the loxP-flanked STOP cassette upstream of tdTomatowith andwithout Cre recombination. (B) Schematic of the LNP formulation process (see amore detailed
description in Figure S4). (C) Diameter distribution for LNP-1 and LNP-2. (D) Zeta potential distribution for LNP-1 and LNP-2.
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expression was comparable with that of previously published10 Luc
expression (Figure S5) for LNP-1, suggesting that the Ai14/Cre
mRNA model can successfully describe the whole-organ expression
of protein from vectored mRNA.
Characterization of a New Formulation with Whole-Organ
Imaging
Recently, a publication by Kranz et al.13 reported that FLuc-encoding
mRNA-LNPs could be redirected to the lungs by increasing the zeta po-
tential of the LNP. To this end, we sought to formulate a new, more
positively charged version of our LNP (LNP-2) and examine its tissue
delivery properties (Figure 1D; Figure S4). As hypothesized, intrave-
nous administration of LNP-2 encapsulating Cre mRNA to Ai14
mice resulted in signiﬁcant tdTomato expression in the lungs (Figures
2B and 2C), consistent with the related formulation and data generated
described by Kranz et al.13 with FLuc mRNA. As previously observed
with LNP-1, no observable whole-organ ﬂuorescence was found in
C57BL/6mice administered LNP-2 formulated with GFP or tdTomato
mRNAat a 0.3mg/kg (approximately 5mg) dose (Figure 2B). To test the
sensitivity of our Ai14/Cre mRNA model, we performed a dose-
response experiment with LNP-2 in the lungs and detected tdTomato
expressionby IVIS atmRNAdoses as lowas 0.01mg/kg (approximately
200 ng) (Figures 2D and 2E) Importantly, tdTomato expression was
dose-dependent, suggesting that tdTomato expression can be used
both as a proxy for vectored mRNA transfection efﬁcacy and to poten-
tially estimate the percentage of transfected cells in a given tissue.
Two-Photon Microscopy for the Ai14/Cre mRNA Model
One potential advantage of the Ai14/Cre mRNA model over
traditional FLuc reporter models is the ability to rapidly perform
ﬂuorescence microscopy to probe the cellular structure of
tdTomato-expressing tissues and ﬂow cytometry to identify
tdTomato-expressing cell populations. Although FLuc would require
additional secondary antibody staining (which is also more disruptive
for intracellular proteins like FLuc because of the need to permeabilize
the cellular membrane), tdTomato-expressing tissues and cells from
Ai14 mice can be immediately analyzed. We chose to ﬁrst perform
two-photon excitation microscopy because it uses freshly isolated tis-
sue and requires no potentially damaging ﬁxation or lengthy antibody
staining steps.28 This technique was used to study the liver, spleen,
and lung tissue architecture of LNP-1- and LNP-2-administered
Ai14 mice (Figure 3), revealing tdTomato expression in liver cells
(Figure 3A), spleen cells (Figure 3B), and cells lining both exterior
(Figure 3C) and interior (Figure 3D) blood vessels of the lung.
Microscopy experiments for LNP-1 injected Ai14 mice revealed
tdTomato expression in liver cells (Figure 3A). We postulate these
tdTomato+ cells to be hepatocytes because their morphology is
cuboidal,29 and previous small interfering RNA (siRNA) formula-
tions made with LNPs similar to LNP-1 were found to silence expres-
sion of a hepatocyte-speciﬁc protein in vivo.30 The spleen (Figure 3B)
has a high degree of autoﬂuorescence because of the abundance of
phagocytic cells that endocytose autoﬂuorescent debris and dead cells,
Figure 2. Whole-Organ Fluorescence for the Ai14/Cre mRNA Mouse Model
(A and B) Representative (n = 3, 1 pictured) GFP or tdTomato expression in three organs for (A) LNP-1- or (B) LNP-2-injected mice under IVIS imaging. LNPs with GFP and
tdTomatomRNAwere administered to C57BL/6mice (24 hr), and LNPswith CremRNAwere administered to Ai14mice (48 hr). Control mice are PBS-treated C57BL/6mice.
(C) Biodistribution of tdTomato fluorescence for LNP-1 and LNP-2 in Ai14 mice. (D) tdTomato expression in the lungs for LNP-2 in Ai14 mice at various doses under IVIS
imaging. (E) Quantification of (D). The data in (C) and (E) are presented as mean + SD, n = 3.
www.moleculartherapy.org
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but tdTomato+ cells are still clearly visible. For LNP-2-administered
Ai14 mice, we observed tdTomato+ cells that lined exterior blood ves-
sels of the lungs (Figure 3C) and tdTomato+ cells in the interior of the
lungs in the blood vessels surrounding the alveoli (Figure 3D). To
more conclusively identify these transfected lung and spleen cell pop-
ulations, ﬂow cytometry was performed next.
Flow Cytometry of Lung-Targeting Formulations
We then investigated the ability of lung cells isolated from the LNP-2-
administered Ai14 mice to undergo ﬂow cytometry. As observed for
whole-organ imaging, ﬂow cytometry analysis could not detect GFP
or tdTomatoﬂuorescence abovebackground forwild-typemice admin-
istered LNP-2 formulated with GFP or tdTomato mRNA (Figure 4A).
However, a strong tdTomato signal was observed in CD31+ (endothe-
lial) cells of the lung forAi14mice administeredLNP-2 formulatedwith
Cre mRNA (Figure 4A). A 2D plot of CD31 versus tdTomato for all
lung cells conﬁrmed that tdTomato-positive cells were nearly exclu-
sively CD31+ (endothelial) lung cells (Figure 4B), with over 75% of iso-
lated CD31+ lung cells expressing tdTomato at the highest tested dose
(0.3 mg/kg) (Figure 4C). At the lowest dose tested (0.01 mg/kg), our
Ai14/Cre mRNA model could still clearly identify a tdTomato+ popu-
lation comprising only 0.4% of all CD31+ lung cells.
Kranz et al.13 previously reported that mRNA-LNPs could be redir-
ected to the lungs by increasing their cationic character but did not
identify which cell types were transfected. For the ﬁrst time, we iden-
tify endothelial cells as the primary transfected lung cell population
when mice are administered LNP-2, a newly described, more cationic
version of LNP-1, using two methods of detection (Figures 3 and 4).
The observation of endothelial cell targeting by cationic LNPs
matches reports of previous lung-targeting siRNA-based cationic for-
mulations that silenced protein expression in lung endothelial cells
but not epithelial or immune cell populations in the lung.31,32 The
Figure 3. Two-Photon Excitation Microscopy of
Tissues for the Ai14/Cre mRNA Mouse Model
(A) Liver cells treated with LNP-1. (B) Spleen cells treated
with LNP-1. (C) Blood vessel on the exteriorof a lung treated
with LNP-2. (D) Interior of a lung treated with LNP-2. Scale
bars, 100 mm. Gray, collagen I (emission wavelength [Em.]
425/30 nm); green, tissue autofluorescence (Em. 525/
45 nm); red, tdTomato (Em. 607/70 nm).
ability to selectively transfect lung endothelial
cells with therapeutic mRNAs is important for
many clinical applications, including pulmo-
nary hypertension33 and cancer.34
FlowCytometry to Identify Rare Populations
in the Spleen
We next aimed to compare the efﬁcacy of two
mRNA delivery vectors in a more complex pop-
ulation of cells; furthermore, we sought to iden-
tify rarer transfected cell populations that would
challenge the sensitivity of the Ai14/Cre mRNA model for visualiza-
tion. We chose to study the immune cell population of the spleen
because LNP-1 and LNP-2 were both identiﬁed to weakly transfect
spleen cells (Figures 2A and 2B), and the spleen contains a variety
of therapeutically important immune cells involved in both the innate
and adaptive immune responses.35 Although a majority of lung
CD31+ cells expressed tdTomato in LNP-2-treated mice, CD45+
spleen cells expressing tdTomato in LNP-1-treated mice are much
less common (Figure 5A) and only observable in the Cre/Ai14 mouse
model.
Flow cytometry analysis of Ai14 mice administered LNP-1 and
LNP-2 identiﬁed a wide variety of tdTomato+ spleen immune cells
(Figure 5B). Notably, LNP-1 resulted in greater proportions of all
measured tdTomato+ splenic CD45+ populations compared with
LNP-2, matching the observation that whole-spleen tdTomato ﬂuo-
rescence is signiﬁcantly greater for LNP-1 than LNP-2 (Figures 2A
and 2B; Figure S6). Compared with other CD45+ cells, both LNP-1
and LNP-2 transfected a greater proportion of macrophages
(CD11b+, F4/80+) than any other cell type. Although macrophages
made up less than 1% of CD45+ cells, they accounted for approxi-
mately 25% of the total tdTomato+ CD45+ cells in the spleen
(Figure 5C).
siRNA-formulated lipid nanoparticles similar in composition to
LNP-1 have been found previously to silence protein predominately
in hepatocytes with only weak silencing in splenic myeloid cells.30
However, no further transfected splenic cell types were identiﬁed
with siRNA, and the ability of LNP-1-type formulations to transfect
splenic cells with mRNA has not yet been investigated. In the
present study, with mRNA-formulated LNP-1 vectors in the Ai14/
Cre mRNA model, we discovered many additional splenic cell types
with clearly identiﬁable mRNA-induced tdTomato+ populations.
Molecular Therapy: Nucleic Acids
58 Molecular Therapy: Nucleic Acids Vol. 10 March 2018
Excitingly, LNP-1 promoted mRNA expression in many cell types
important for mRNA immunotherapies,6,35 including lymphocytes
and antigen-presenting cells (Figure 5) with approximately 4% of
splenic dendritic cells and over half of macrophages transfected,
making LNP-1 an attractive candidate for future studies with
mRNA-based vaccines or immuno-modulators. It should be noted
that, although tdTomato expression was observed in a wide variety
of differentiated immune cells in the spleen at the time of isolation,
we cannot rule out the possibility that such cells were progenitor cells
or circulating immune cells at the time of transfection, and, thus, the
number of transfected cells may be over-estimated.
The discovery of these transfected cell types in vivo would not have
been possible or would have required signiﬁcantly more labor with
vectored siRNA. It has been common practice to determine
whether siRNA vectors were efﬁcacious in particular cell types
by designing siRNA against proteins only expressed in those cells
(e.g., Factor VII for hepatocytes30,36,37 and Tie2 for endothelial
cells31,32); mRNA offers no such analog because any cell with the
proper ribosomal machinery should, in principle, be capable of
translation. Many delivery vectors originally designed for siRNA
delivery have been re-engineered for mRNA delivery.3 The identi-
ﬁcation of many new cell populations successfully transfected by
mRNA vectors like LNP-1 and LNP-2 suggests that, unless the
mRNA versus siRNA payload dramatically affects vector transfec-
tion ability, siRNA vectors may have been transfecting more cell
types than originally thought and may have been limited in efﬁcacy
only by siRNA potency.
Comparison of the Ai14/Cre mRNA Model with Other Systems
Many potential mRNA therapies could beneﬁt from formulations
capable of providing selective delivery to the required tissue and
cell type in vivo. Different mRNA imaging methods provide for
different levels of sensitivity. One of the most common reporters
for surveying in vivo mRNA activity is FLuc mRNA, which, when
translated into protein and activated by substrate, emits measurable
light. However, identiﬁcation of transfected cell populations by
FLuc is challenging because immunohistochemistry or ﬂow cytome-
try would require incubation with secondary anti-FLuc ﬂuorescently
tagged antibodies that must permeabilize and potentially disrupt the
cellular membrane.38 Because of these challenges, alternate ap-
proaches have often been taken. For example, two independent re-
ports conﬁrmed the transfection of splenic CD11c+ cells with an
mRNA vector by comparing FLuc expression between wild-type
and genetically modiﬁed CD11c-depleted mice;13,39 however, this
generalized approach would require a different knockout mouse for
every potential transfected cell type of interest, which researchers
would also need to know a priori.
Alternatively, some publications have used ﬂuorophore-labeled
RNAs in vivo to study the biodistribution and cellular localization
of vectored nucleic acids.14,32,40,41 However, tissue and cellular trans-
fection of the mRNA itself does not always correlate well with trans-
lation of the desired protein.14 Furthermore, this method cannot
distinguish between ﬂuorophore-labeled mRNA adhered to the sur-
face of cells, those that are trapped in cellular compartments such
as endosomes, and those that have successfully transfected into the
Figure 4. Single-Cell Analysis of Lung Cells from the Ai14/Cre mRNA Mouse Model
(A) Representative (n = 3, 1 pictured) histograms of GFP or tdTomato signal for CD31+ (endothelial) lung cells in LNP-2-administered mice, determined by flow cytometry.
LNPs with GFP and tdTomato mRNA were administered to C57BL/6 mice (24 hr), and LNPs with Cre mRNA were administered to Ai14 mice (48 hr). Control mice are PBS-
treated C57BL/6 mice. (B) Representative fluorescence-activated cell sorting (FACS) plot of lung CD31 versus tdTomato for LNP-2-injected (left) and control-injected (right)
mice. (C) Percent of lung CD31+ cells that are tdTomato+ at multiple doses in LNP-2-injected Ai14 mice, presented as mean + SD, n = 3.
www.moleculartherapy.org
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cytoplasm. Because knowing the biodistribution of mRNA and vector
materials is indeed important for understanding both toxicity and
pharmacokinetics, the use of ﬂuorophore-labeled mRNA vectors in
concert with the Ai14/Cre mRNAmodel would give a more complete
description of the in vivo behavior of mRNA delivery vectors.
In this report, we present a mouse model to determine the location of
mRNA expression in vivo with single-cell resolution using commer-
cially available reagents andmice. Using previously reported and novel
lipid nanoparticle vectors, we deliver mRNA encoding for Cre protein
to Ai14 mice, which express tdTomato upon Cre recombination
(Figure 1). When the same lipid nanoparticles were formulated with
mRNAsencodingﬂuorescent protein (GFPand tdTomato) andadmin-
istered to wild-type mice, no ﬂuorescence was observed above
background in vivo forwhole organs or individual cell populations (Fig-
ures 2, 4, and 5), which highlights the signiﬁcantly improved sensitivity
of the Cre/Ai14model. It should be noted that the GFP, tdTomato, and
Cre mRNAs used in these experiments are commercially available and
differed only in their coding regions; they had identical 50 caps, UTR se-
quences, poly(A) tail lengths, and base modiﬁcations, all of which are
known to strongly inﬂuence the potency of the mRNA.1 We found
one report in the literature of measuring expression from GFP
mRNA in vivowithﬂowcytometry,13 but theGFPmRNAwas delivered
at far higher doses than we demonstrate (1 mg/kg versus as low as
0.01 mg/kg), and the GFP mRNA was also highly optimized and syn-
thesized in-house.42 Because both the Ai14 mice and the Cre mRNA
are readily commercially available, the Ai14/Cre mRNA model would
permit researchers without access to often proprietary mRNA optimi-
zation algorithms to screenmRNAvectors in vivo for theﬁrst time at far
lower doses and with less potent delivery materials.
Applications of the Ai14/Cre mRNA Model
Although it has signiﬁcant advantages, the Ai14/Cre mRNA model
does have limitations compared with traditional FLuc models. Genet-
ically engineered Ai14 mice are more expensive to purchase than
standard C57BL/6 or other mouse strains, and FLuc mRNA remains
a fast (luminescence visible minutes after substrate injection) and
robust (low signal-to-noise ratio) method to screen mRNA expres-
sion in tissues in vivo. FLuc mRNA can also be non-invasive, making
it appropriate for longitudinal studies to measure protein expression
over time. Additionally, although FLuc expression (the output) in a
given tissue should be directly proportional to the quantity of trans-
fected mRNA (the input), the Ai14/Cre mRNAmodel is a binary “on/
off” system, where the successful transfection of one Cre mRNA
would have the same tdTomato expression as many Cre mRNAs.
Thus, we envision the Ai14/Cre mRNA system to be used not as a
Figure 5. Single-Cell Analysis of Spleen Cells from the Ai14/Cre mRNA Mouse Model
(A) Representative (n = 3, 1 pictured) histograms of tdTomato signal for CD45+ (immune) spleen cells in LNP-1-administered mice, determined by flow cytometry. The y axis
on the histograms in the bottom row is enlarged to highlight the tdTomato signal. LNPs with GFP and tdTomato mRNA were administered to C57BL/6 mice, and LNPs with
Cre mRNA were administered to Ai14 mice. Control mice are PBS-treated C57BL/6 mice. (B) Percent of CD45+ spleen cells that are tdTomato+ in LNP-1- or LNP-2-injected
Ai14 mice, presented as mean + SD, n = 3. (C) Distribution of CD45+ splenic cells (top) and tdTomato+ CD45+ splenic cells (bottom), presented as mean, n = 3.
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replacement of FLuc models but, rather, primarily for identifying
transfected cell populations in vivo and discovering low-expressing
tissues or rare cell types too weak to be visualized with FLuc. We
also envision the system to be used for determining these hits at lower
doses, longer time points, and with less overall efﬁcacious vectors.
The binary nature of the Ai14/Cre mRNA mouse model can provide
information difﬁcult to observe using a simple FLuc system. For
example, tdTomato expression following treatment with the LNP-2
formulation saturates around a dose of 0.1 to 0.3 mg/kg in the lungs
(Figures 2E and 4B), suggesting that a certain number of endothelial
cells might be incapable of transfection regardless of dose escalation.
Additionally, a binary readout in which only one Cre protein (from
delivered CremRNA)must transfect the nucleus to express tdTomato
is highly analogous to genome editing applications such as the
CRISPR/Cas system, in which one Cas9 protein (from delivered
Cas9 mRNA) must transfect the nucleus to edit a gene. Thus, we
anticipate the Ai14/Cre mRNA mouse model to be highly useful for
researchers performing mechanistic analyses of in vivo mRNA deliv-
ery and for those studying in vivo genome editing with nuclease-en-
coding mRNAs. A recent publication further demonstrated the utility
of reporter mice similar to Ai14 mice for CRISPR applications by co-
delivering Cas9 mRNA and single guide RNA (sgRNA) against loxP,
thus cutting out the STOP cassette and inducing tdTomato in trans-
fected cells.43
Conclusions
In conclusion, we have demonstrated the use of a mouse model in
which mRNA expression can be identiﬁed with single-cell resolution
in vivo. Because of the increased sensitivity of the Ai14/Cre mRNA
model over traditional reporter mRNAs (i.e., luciferase, GFP, or
tdTomato), we discovered that a previously reported lipid nanopar-
ticle mRNA formulation is capable of transfecting splenic lympho-
cytes and antigen-presenting cells, and we designed a new mRNA
formulation capable of transfecting lung endothelial cells. We pro-
pose that this described Ai14/Cre mRNA mouse model be used
together with traditional luciferase models in future experiments to
screen and optimize mRNA delivery vectors for therapeutic applica-
tions, including protein replacement therapies, genomic engineering,
and mRNA vaccines.
MATERIALS AND METHODS
mRNA
Commercially available mRNA encoding nuclear localization signal
(NLS)-Cre and EGFP were purchased from TriLink Biotechnologies
(San Diego, CA). mRNA encoding tdTomato was custom-synthe-
sized by TriLink according to the same speciﬁcations as Cre
and GFP. All mRNAs were 100% modiﬁed with pseudouridine and
5-methylcytidine, capped with Cap 0, and polyadenylated.
Lipid Nanoparticle Formulation
The ethanol phase contained a mixture of cKK-E12 (prepared as
described previously,30 courtesy of Shire Pharmaceuticals, Lexington,
MA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, Avanti
Polar Lipids, Alabaster, AL), 1,2-dioleoyl-3-trimethylammonium-pro-
pane (DOTAP, Avanti), cholesterol (Sigma), and/or 1,2-dimyristoyl-
sn-glycero-3-phosphoethanolamine-N-(methoxy[polyethylene gly-
col]-2000) (C14 PEG 2000, Avanti) in differing molar ratios
(Table S1) for LNP-1 and LNP-2. The aqueous phase contained
mRNA in 10 mM citrate buffer (pH 3). Syringe pumps were used to
mix the ethanol and aqueous phases together at a 1:3 volume ratio in
a microﬂuidic chip device as described previously.44 The resulting
LNPs were dialyzed against 1 PBS in a 20,000molecular weight cutoff
(MWCO) cassette at 4C for 2 hr.
Lipid Nanoparticle Characterization
To calculate the mRNA encapsulation efﬁciency, a modiﬁed
Quant-iT RiboGreen RNA assay (Invitrogen) was performed as
described previously.45 The diameter (measured by intensity) and
polydispersity of the LNPs were measured using dynamic light scat-
tering (ZetaPALS, Brookhaven Instruments). Zeta potential was
measured using the same instrument in a 0.1 PBS solution.
Animal Experiments
Animal studies were approved by the Massachusetts Institute of
Technology (MIT) Institutional Animal Care and Use Committee
and were consistent with local, state, and federal regulations as appli-
cable. Female B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J (Ai14,
stock no. 007914) mice and control C57BL/6 mice were purchased
from Jackson Laboratory (Bar Harbor, ME). Mice (18–22 g) were
intravenously injected with LNPs via the tail vein at a dose of
0.3 mg/kg, unless otherwise noted, for dose-response experiments.
For GFP and tdTomato mRNA experiments, in vivo measurements
were taken 24 hr post-injection (according to the half-life of the pro-
teins). For Cre mRNA experiments, measurements were taken 48 hr
post-injection. Mice were euthanized by carbon dioxide asphyxiation.
Whole-Organ Imaging
To measure whole-organ ﬂuorescence, organs were collected and
measured using an IVIS imaging system (PerkinElmer, Waltham,
MA) and quantiﬁed using LivingImage software (PerkinElmer).
Two-Photon Excitation Microscopy
Imaging was performed on an FV-1000MPE microscope (Olympus
America, Waltham MA) using a 25, numerical aperture (N.A.)
1.05 water objective. Excitation was achieved using a DeepSee Tai-
sapphire femtosecond pulse laser (Spectro-Physics, Santa Clara,
CA) at 840 nm. The emitted ﬂuorescence was collected by photomul-
tiplier tubes (PMTs) with emission ﬁlters of 425/30 nm for collagen 1,
525/45 nm for tissue autoﬂuorescence, and 607/70 nm for tdTomato.
Collagen 1 was excited by second harmonic generation and emits as
polarized light at half the excitation wavelength. All images were pro-
cessed using ImageJ.
Flow Cytometry
Spleen single cell suspensions were prepared as described previ-
ously.46 To prepare lung single-cell suspensions, lungs were digested
in a mixture of collagenase I (450 U), collagenase XI (125 U), and
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DNase I (2 U) in 1 mL at 37C for 1 hr. The digest was passed through
a 70-mm ﬁlter. Following centrifugation and removal of supernatant,
cells were treated with red blood cell (RBC) lysis buffer for 10 min at
4C and then passed through a 40-mm ﬁlter.
After single-cell suspensions were generated, cells were stained with a
mixture of anti-mouse antibodies at 1:300 dilution in ﬂow buffer (PBS
containing 0.5% BSA and 2 mM EDTA). The antibodies included
T cell receptor b (TCR-b, clone H57-597), CD19 (clone 6D5),
CD11b (clone M1/70), Ly-6G (clone 1A8), CD45 (clone 30-F11),
F4/80 (clone BM8), CD11c (clone N418), CD31 (clone 390), and
EpCAM (clone G8.8). Antibodies were purchased from BioLegend
(San Diego, CA), and data were collected using a BD LSR II cytometer
(BD Biosciences). Data were analyzed with FlowJo software (Ashland,
OR).
Splenic cell populations were identiﬁed as follows: T cells: CD45+,
CD11b, TCR-b+; B cells: CD45+, CD11b, CD19+; neutrophils:
CD45+, CD11b+, Ly-6G+; macrophages: CD45+, CD11b+, F4/80+;
dendritic cells: CD45+, CD11b+, CD11c+; other myeloid cells:
CD45+, CD11b+, Ly-6G, F4/80, CD11c. Lung cell populations
were identiﬁed as follows: endothelial cells, CD31+; epithelial cells,
EpCAM+; immune cells, CD45+.
In Vitro Experiments
HeLa cells (ATCC, Manassas, VA) were cultured in high-glucose
DMEM (Thermo Fisher Scientiﬁc) supplemented with 10% fetal
bovine serum. Cells were maintained at 37C and 5% CO2. Cells
were plated at 20,000 cells/well in a clear-bottom, black-walled, 96-
well plate. After 24 hr, the medium in each well was replaced with
150 mL of medium containing GFP or tdTomato mRNA-LNPs or
mRNA-Stemfect complexes. The mRNA transfection reagent Stem-
fect (Stemgent, Lexington, MA) was used according to the manufac-
turer’s protocol. After another 24 hr, the ﬂuorescence was measured.
Fluorescence microscopy was performed with an EVOS FL cell imag-
ing system (Thermo Fisher Scientiﬁc). To quantify the ﬂuorescence,
cells were lysed with 50 mL of Cell Lytic M for 10 min at 37C at
400 rpm. 150 mL of PBS was added to each well, and ﬂuorescence
was measured with a Tecan Inﬁnite m200 Pro microplate reader.
Statistics
To compare two groups, a Student’s t test was performed, assuming a
Gaussian distribution with unequal variances. Statistical signiﬁcance
was deﬁned with an alpha level of 0.05. All statistical analyses were
performed using GraphPad Prism 7 software (La Jolla, CA).
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